The experts and researchers of Wuhan, China, reported numerous unexplained pneumonia cases to the World Health Organization, also known as WHO, in December 2020. Severe acute respiratory syndrome coronavirus−2 (SARS‐CoV‐2), a zoonotic pathogen, came into sight, spreading coronavirus disease 2019 (COVID‐19) worldwide. Association of cutaneous signs and symptoms with COVID‐19 is being studied worldwide, principally determining if these dermatoses can help in early recognition of SARS‐CoV‐2 infection. These dermatological manifestations can range from an erythematous rash, urticaria to livedo reticularis and acrocyanosis in patients of all age groups. Correspondingly, dermatologists treating COVID‐19 patients suffering from inflammatory dermatoses with biologics or immunomodulators should exert caution and use specific protocols to adjust these medications’ doses.
Prevention of person‐to‐person transmission of COVID‐19 is being promoted universally, using personal protective equipment or PPE, hand washes, and hand sanitizers around the clock. However, an array of cutaneous adverse effects such as contact dermatitis, irritant contact dermatitis, friction blisters, contact urticaria, acne, and infections are associated with the use of PPE. Extra‐pulmonary manifestations of COVID‐19 are still emerging in the community, and physicians and researchers are working together globally to strengthen these patients’ clinical management. Cases of COVID‐19 continue to rise across the world, and an unprecedented approach has been taken to develop effective vaccines and therapeutic strategies against existing and forthcoming mutagenic strains of SARS‐CoV‐2.
Ref: https://onlinelibrary.wiley.com/doi/10.1111/ijd.15257
